TRANSITION THERAPEUTICS INC 
By
TORONTO, ON, August 30th, 2012 - Transition Therapeutics Inc.
("Transition" or the "Company") (TSX:TTH,
NASDAQ:TTHI) today announced that its licensing partner, Elan
Corporation, plc ("Elan") has commenced a Phase 2,
placebo-controlled, safety and efficacy study of oral ELND005
as an adjunctive maintenance treatment in patients with
Bipolar I Disorder (BPD 1) to delay the time to occurrence of
mood episodes. As the first patient has been dosed in this
study, Transition will receive a milestone payment of US$ 11
million from Elan.
This bipolar clinical study is expected to enroll approximately 400 patients with BPD 1. Additional information on the study design and protocol for this study ELND005-BPD201 can be found at http://clinicaltrials.gov/
Bipolar I Disorder (BPD) is a severe form of BPD, also commonly known as manic depressive illness. It is a psychiatric disorder characterized by excessive swings in a person
This bipolar clinical study is expected to enroll approximately 400 patients with BPD 1. Additional information on the study design and protocol for this study ELND005-BPD201 can be found at http://clinicaltrials.gov/
Bipolar I Disorder (BPD) is a severe form of BPD, also commonly known as manic depressive illness. It is a psychiatric disorder characterized by excessive swings in a person
Share
© Publicnow - 2012
